Please assess the completion status of the following clinical trial:

Trial Title: Dopamine in Acute Decompensated Heart Failure II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with New York Heart Association (NYHA) functional class IV heart failure according to the American Heart Association (AHA) classification, namely dyspnea on minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea,~* signs of congestion (third heart sound or pulmonary rales on physical examination),~* pulmonary congestion on chest x-ray,~* serum B-type natriuretic peptide levels \> 400 pg/ml or NT-proBNP \> 1500 pg/ml,~* echocardiographic documentation of systolic or diastolic dysfunction,~* age \>18 years old,~* on medical therapy with an ACE-inhibitor and/or a β-blocker,~* experiencing an acute decompensation of known chronic HF,~* baseline oxygen saturation \<90% on admission arterial blood gas~Exclusion Criteria:~* acute de novo HF;~* severe renal failure (serum creatinine \>200 μmol/L or GFR \<30 ml/min/1.73m2)~* admission systolic blood pressure \<90 mm Hg;~* severe valvular disease;~* known adverse reactions to furosemide or dopamine;~* HF secondary to congenital heart disease;~* a scheduled procedure with a need for IV contrast dye;~* a scheduled cardiac surgery within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-dose furosemide (Type: ACTIVE_COMPARATOR): High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
- Low-dose furosemide (Type: ACTIVE_COMPARATOR): Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
- Low-dose furosemide combined with low-dose dopamine (Type: ACTIVE_COMPARATOR): Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).